Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of international research on androgen deprivation therapy (ADT) for prostate cancer ...

Men with prostate cancer who were treated with the GnRH agonist leuprolide had significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix.

U.S. study supports findings from a global trial using an external control arm ...

Recently, the research group led by Dr. Dechao Feng, Lecturer at University College London (UCL) and Distinguished Research ...

If you’ve been diagnosed with advanced prostate cancer, there’s a good chance you’ll receive androgen deprivation therapy (ADT) at some point, as ADT is a mainstay of prostate cancer treatment. It ...

In a pooled analysis, longer duration of androgen deprivation therapy (ADT) was associated with nonlinear improvements in outcomes in men with prostate cancer receiving definitive radiotherapy.

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer. The combination of Nubeqa (darolutamide) ...

The ARASEC study prospectively examined darolutamide plus ADT in US men with mHSPC, but used a historical control group receiving ADT monotherapy from the phase 3 CHAARTED trial for matching and ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond 9 to 12 months of ADT. HealthDay News — Increasing duration of androgen deprivation therapy (ADT) ...

In men with hormone-sensitive metachronous oligometastatic prostate cancer, the use of stereotactic body radiotherapy (SBRT) commonly delayed the need for long-term ADT and provided durable disease ...

New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients ...

This medication is a beneficial addition to your prostate cancer treatment plan — but it doesn’t come without risks. Here’s how to stay ahead of potential side effects. If you’ve been diagnosed with ...